The resolution introduced on February 27, 2025, designates the first full week in May as Tardive Dyskinesia Awareness Week. It highlights the connection between the use of antipsychotic medications, which are often necessary for managing serious mental illnesses, and the risk of developing tardive dyskinesia (TD), a condition characterized by uncontrollable movements. The resolution emphasizes that a significant portion of individuals living with TD remain undiagnosed, and it calls for increased awareness and education regarding the condition, particularly for healthcare providers and patients.

Furthermore, the resolution underscores the importance of early detection and intervention in improving the quality of life for those affected by TD. It encourages routine screenings for TD in line with clinical guidelines and supports efforts to raise awareness about the condition's causes and symptoms. The Senate also directs that a copy of the resolution be sent to Neurocrine Biosciences to further promote awareness and education regarding TD.